DARPin delay drops Allergan despite earnings rise
This article was originally published in Scrip
Executive Summary
Allergan reported an 18% earnings increase and an 8.4% rise in net product sales for the first quarter of 2013, but its stock fell 13.1% to $98.67 per share on 1 May after the company revealed delays for two key pipeline programs, including its Phase II anti-VEGF candidate for the treatment of wet age-related macular degeneration (AMD).